[Association of single nucleotide polymorphism in matrix metalloproteinases promoter with susceptibility to ovarian cancer].

OBJECTIVE: To investigate the association of single nucleotide polymorphism in matrix metalloproteinase (MMP)-1 and MMP-3 promoter with susceptibility to ovarian cancer. METHODS: The genotype of MMP-1 and MMP-3 gene promoter region was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 122 ovarian cancer patients (ovarian cancer group) and 151 unrelated healthy women (control group). RESULTS: The frequencies of 2G and 1G alleles in ovarian cancer group were 68.0%, 32.0% and in control group 66.9%, 33.1%, with no significant difference between the two groups (P > 0.05); the genotype frequencies of 1G/1G, 1G/2G, 2G/2G in ovarian cancer group (16.4%, 31.1% and 52.5%) was not significantly different from that in control group (16.6%, 33.1% and 50.3%) (P > 0.05). Compared to 1G/1G genotype, neither 2G/2G nor in combination with 1G/2G genotype significantly modified the risk of developing ovarian cancer. The adjusted odds ratio was 1.05 (95% CI = 0.53-2.07) and 1.00 (95% CI = 0.52-1.90), respectively. The frequencies of 5A and 6A alleles in MMP-3 in ovarian cancer group were 17.2%, 82.8% and in control group 20.2%, 79.8%, with no significant difference between the two groups (P > 0.05). No significant difference in genotype (5A/5A, 5A/6A and 6A/6A) distribution between ovarian cancer and control groups was observed, either. Compared to 6A/6A genotype, 5A/5A plus 5A/6A genotype did not significantly modify the risk of developing ovarian cancer, the adjusted odds ratio was 1.34 (95% CI = 0.81-2.23). 2G allele of MMP-1 and 6A allele of MMP-3 were in linkage disequilibrium (chi(2) = 56.53, P < 0.01). CONCLUSION: MMP-1 and MMP-3 promoter polymorphism is not associated with the susceptibility to ovarian cancer.